Label: SODIUM POLYSTYRENE SULFONATE powder, for suspension

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 5, 2019

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use Sodium Polystyrene Sulfonate Powder, for Suspension safely and effectively. See full prescribing information for Sodium Polystyrene Sulfonate Powder, for Suspension.
    Sodium Polystyrene Sulfonate Powder, for Suspension, for oral or rectal use
    Initial U.S. Approval: 1958

    INDICATIONS AND USAGE

    Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia (1).

    Limitation of Use:

    Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action (1).

    DOSAGE AND ADMINISTRATION

    Oral: The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily (2.1).

    Rectal: The average adult dose is 30 g to 50 g every six hours (2.1).

    DOSAGE FORMS AND STRENGTHS

    Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder (3)

    CONTRAINDICATIONS

    ● Hypersensitivity to polystyrene sulfonate resins (4)

    ● Obstructive bowel disease (4)

    ● Neonates with reduced gut motility (4)

    WARNINGS AND PRECAUTIONS

    Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported (5.1).
    Electrolyte Disturbances: Severe hypokalemia can occur. (5.2).
    Fluid overload in patient sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload. (5.3).
    Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. (5.4).

    ADVERSE REACTIONS

    Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting (6).

    To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC 1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Take other orally administered drugs at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension (7.1).
    Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis (7.2).
    Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended (7.3).

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 11/2019

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Sodium Polystyrene Sulfonate Powder, for Suspension is indicated for the treatment of hyperkalemia.

    Limitation of Use:

    Sodium Polystyrene Sulfonate Powder, for Suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2)].

  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Information

    Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [see Warnings and Precautions (5.5) and Drug Interaction (7)]

    2.2 Recommended Dosage

    The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

    Oral

    The average total daily adult dose of Sodium Polystyrene Sulfonate Powder, for Suspension is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.

    Rectal

    The average adult dose is 30 g to 50 g every six hours.

    2.3 Preparation and Administration

    Prepare suspension fresh and use within 24 hours.

    Do not heat Sodium Polystyrene Sulfonate Powder, for Suspension as it could alter the exchange properties of the resin.

    One level teaspoon contains approximately 3.5 g of Sodium Polystyrene Sulfonate Powder, for Suspension and 15 mEq of sodium.

    Oral Suspension

    Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [see Warnings and Precautions (5.4)].

    Enema

    After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.

    Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.

    Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.

  • 3 DOSAGE FORMS AND STRENGTHS

    Sodium Polystyrene Sulfonate Powder, for Suspension is a cream to light brown, finely ground powder and is available in 453.6 g jars.

  • 4 CONTRAINDICATIONS

    Sodium Polystyrene Sulfonate Powder, for Suspension is contraindicated in patients with the following conditions:

    ● Hypersensitivity to polystyrene sulfonate resins

    ● Obstructive bowel disease

    ● Neonates with reduced gut motility

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Intestinal Necrosis

    Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with Sodium Polystyrene Sulfonate Powder, for Suspension use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.

     
    ● Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
     
    ● Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction).
     
    Discontinue use in patients who develop constipation.

    5.2 Electrolyte Disturbances

    Monitor serum potassium during therapy because severe hypokalemia may occur.

    Sodium Polystyrene Sulfonate Powder, for Suspension is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving Sodium Polystyrene Sulfonate Powder, for Suspension.

    5.3 Fluid Overload in Patients Sensitive to High Sodium Intake

    Each 15 g dose of Sodium Polystyrene Sulfonate Powder, for Suspension contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.

    5.4 Risk of Aspiration

    Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer Sodium Polystyrene Sulfonate Powder, for Suspension with the patient in an upright position.

    5.5 Binding to Other Orally Administered Medications

    Sodium Polystyrene Sulfonate Powder, for Suspension may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after Sodium Polystyrene Sulfonate Powder, for Suspension. Patients with gastroparesis may require a 6 hour separation. [see Dosage and Administration (2.1) and Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed elsewhere in the labeling:

    ● Intestinal Necrosis [see Warnings and Precautions (5.1)]

    ● Electrolyte Disturbances [see Warnings and Precautions (5.2,5.3)]

    ● Aspiration [see Warnings and Precautions (5.4)]

    The following adverse reactions have been identified during post-approval use of Sodium Polystyrene Sulfonate Powder, for Suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

    Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)

    Metabolic: systemic alkalosis

  • 7 DRUG INTERACTIONS

    7.1 General Interactions

    No formal drug interaction studies have been conducted in humans.

    Sodium Polystyrene Sulfonate Powder, for Suspension has the potential to bind other drugs. In in vitro binding studies, Sodium Polystyrene Sulfonate Powder, for Suspension was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. Binding of Sodium Polystyrene Sulfonate Powder, for Suspension to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time Sodium Polystyrene Sulfonate Powder, for Suspension is administered. Administer Sodium Polystyrene Sulfonate Powder, for Suspension at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.

    7.2 Cation-Donating Antacids

    The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis

    7.3 Sorbitol

    Sorbitol may contribute to the risk of intestinal necrosis [see Warnings and Precautions (5.1)] and concomitant use is not recommended.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

    8.2 Labor and Delivery

    Risk Summary

    Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.

    8.4 Pediatric Use

    Studies of safety and efficacy have not been conducted in pediatric patients.

    In pediatric patients, as in adults, Sodium Polystyrene Sulfonate Powder, for Suspension is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.

    In neonates, Sodium Polystyrene Sulfonate Powder, for Suspension should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with Sodium Polystyrene Sulfonate Powder, for Suspension use [see Warnings and Precautions (5.4)].

  • 10 OVERDOSAGE

    Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

  • 11 DESCRIPTION

    Sodium Polystyrene Sulfonate Powder, for Suspension is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:

    L:\Labeling Department\ANDA\Sodium Polystyrene Sulfonate_SZ- Done\Epic\Package Insert\2017.10 RLD update\Platimun\Docs for Submission\SBS\Structure

    The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.

    One gram of Sodium Polystyrene Sulfonate Powder, for Suspension contains 4.1 mEq of sodium.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Sodium Polystyrene Sulfonate Powder, for Suspension is a non-absorbed, cation exchange polymer that contains a sodium counterion.

    Sodium Polystyrene Sulfonate Powder, for Suspension increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.

    As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.

    12.2 Pharmacodynamics

    The effective lowering of serum potassium with Sodium Polystyrene Sulfonate Powder, for Suspension may take hours to days.

    12.3 Pharmacokinetics

    The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.

    Sodium Polystyrene Sulfonate Powder, for Suspension is not absorbed systemically.

    Drug Interactions

    In vitro binding studies showed that Sodium Polystyrene Sulfonate Powder, for Suspension bound significantly to the following tested drugs - warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies have not been performed.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Sodium Polystyrene Sulfonate Powder, for Suspension is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g). NDC 42806-013-96.

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

  • 17 PATIENT COUNSELING INFORMATION

    Drug Interactions

    Advise patients who are taking other oral medication to separate the dosing of Sodium Polystyrene Sulfonate Powder, for Suspension by at least 3 hours (before or after) [see Dosage and Administration (2.1),Warnings and Precautions (5.5), and Drug Interactions (7.1)]

    Rx Only

    Manufactured by:

    Epic Pharma, LLC

    Laurelton, NY 11413

    Rev. 10-2017-00

    MF013REV10/17

    OE1063

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 453.6 g

    sodium-polystyrene-sulfonate-456.6 g.jpg
  • INGREDIENTS AND APPEARANCE
    SODIUM POLYSTYRENE SULFONATE 
    sodium polystyrene sulfonate powder, for suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42806-013
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z) (POLYSTYRENE SULFONIC ACID - UNII:70KO0R01RY) SODIUM POLYSTYRENE SULFONATE4.1 meq  in 1 g
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:42806-013-96453.6 g in 1 JAR; Type 0: Not a Combination Product04/14/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20233304/14/2014
    Labeler - Epic Pharma, LLC (827915443)